PosaconazoleThird Party Manufacturing in India

Posaconazole works by inhibiting the enzyme lanosterol 14-alpha-demethylase, a cytochrome P450-dependent enzyme in fungi. This inhibition blocks the conversion of lanosterol into ergosterol, which is an essential structural component of the fungal cell membrane. The depletion of ergosterol, combined with the accumulation of toxic methylated sterol precursors, compromises the structural integrity and permeability of the cell membrane, leading to fungal cell death and stopping the spread of systemic infection.

Therapeutic Uses

Posaconazole is prescribed for the prevention and treatment of invasive fungal infections:

• Invasive Aspergillosis: Treatment of aggressive lung and systemic infections caused by Aspergillus species.
• Candidiasis: Treatment of severe, refractory esophageal and systemic infections caused by Candida species.
• Fungal Infection Prophylaxis: Prevents invasive fungal infections in severely immunocompromised patients, such as transplant recipients and chemotherapy patients.

Why Manufacturers Choose Posaconazole

Posaconazole is a high-value, critical-care antifungal drug. Sourcing Posaconazole third party manufacturing in India from WHO-GMP certified facilities allows oncology and critical-care distributors to secure stable and high-margin product listings. Sourcing delayed-release tablets (100mg), suspensions, or sterile injections (300mg) requires advanced formulation controls to ensure bioequivalence and clinical stability.

Indian manufacturers offer robust supply chains for high-purity APIs and specialized production blocks, facilitating seamless domestic distribution and global export under compliant guidelines.